Supportive care	4
survival aspects	7
Clinical (qualifier value)	2
Weight measurement scales	3
ADVANTAGE	1
alone	1
Disease	1
Colorectal Cancer	1
Pain	2
Mental association	1
Biomechanical compliance	1
With quality (attribute)	4
Euphoric mood	1
Deferred (qualifier value)	1
ORALIT	1
cm (qualifier value)	1
Median Statistical Measurement	2
Intellectual scale	1
Incidence	1
Nine (qualifier value)	1
symptoms	3
Generalized (qualifier value)	1
Continuance of life	7
Severe (severity modifier) (qualifier value)	2
Random Allocation	1
Overall [Publication Type]	1
Primary	1
Scientific Study	2
High	1
Previous (qualifier value)	1
Groups (qualifier value)	2
physiological aspects	1
week (qualifier value)	3
Group (social concept)	1
Patient Compliance	1
criteria	1
therapeutic aspects	3
Topoisomerase inhibitor (substance)	1
Cell Division	1
Secondary malignant neoplastic disease (disorder)	1
Curved (qualifier value)	1
[D]Abdominal mass (context-dependent category)	1
irinotecan	3
benefits	3
Other	2
Follow-up status (finding)	1
Step (qualifier value)	1
Relationship by association	1
One (qualifier value)	2
Weight Loss	1
Asthenia	1
Pain-Free	1
Life	1
Neutropenia	1
Median (qualifier value)	2
Events (event)	1
Patients	7
Diarrhea	2
Pharmacotherapy	1
DNA Replication	1
Probability	1
Room of building - Study	2
month (qualifier value)	2
Function	1
VALUING	1
Therapeutic procedure	3
Better (qualifier value)	1
More (qualifier value)	1
adverse effects	1
year (qualifier value)	1
incidence of cases	1
Persons	1
Special (qualifier value)	2
Intestinal Obstruction	1
Health Status	1
Function Axis	1
Fluorouracil	1
Questionnaires	1
Variable (qualifier value)	1
ENDPOINT	2
Onset of (contextual qualifier) (qualifier value)	1
Five (qualifier value)	1
Nausea	1
Primary operation (qualifier value)	1
End (qualifier value)	1
Integumentary scale	3
Significant (qualifier value)	2
Chemotherapy-Oncologic Procedure	1
Good (qualifier value)	1
Neoplasm Metastasis	2
pharmacotherapeutic	1
